Duopharma Biotech Bhd’s net profit for the second quarter ended June 30, rose 6% to RM14.73 million from RM13.92 million a year ago, thanks to local sales, but revenue fell by 1.5% to RM143.33 million versus RM145.47 million last year.
“Although 2020 is proving to be more challenging than previous years, we continue to remain cautiously optimistic of our FY2020 performance,“ he said in a statement. “Concurrently, we are preparing for the technology transfer process to Duopharma Biotech of a second product during August 2020.”
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: